TECHNOLOGY AND PIPELINE SUMMARY

Pyrrolobenzodiazepine dimers (PBDs) Provide a Novel “Synthetic Lethal” Approach for the Treatment of Resistant Cancers such as Metastatic Endometrial, Triple-Negative Breast, and/or Metastatic Colorectal Cancers:

IndUS’s novel PBDs are active in cancers associated with the loss of tumor suppression, DNA repair and/or homologous recombination gene function, which are responsible for some of the refractory nature of cancers such as metastatic endometrial, triple-negative breast and/or metastatic colorectal cancers through a novel DNA Damage Response (DDR) pathway. Furthermore, PBDs also exhibit ‘synthetic lethality’, which results in its ability to promote cytotoxicity and death of refractory cancers that have mutations in tumor suppressor functions.

There are no effective treatments available for tumors that have “functional deficiencies” in genes like BRCA1 or BRCA2 (breast cancer); DNA mismatch repair (colon, endometrial, glioblastoma and bladder); PTEN (colon, endometrial, leukemia and breast) and ERCC1 (melanoma). Such tumors remain a highly unmet clinical need and currently few drugs are under development that would specifically target tumors with such ‘loss of function’ in tumor suppressor genes.

There are no effective treatments available for tumors that have “functional deficiencies” in genes like BRCA1 or BRCA2 (breast cancer); DNA mismatch repair (colon, endometrial, glioblastoma and bladder); PTEN (colon, endometrial, leukemia and breast) and ERCC1 (melanoma). Such tumors remain a highly unmet clinical need and currently few drugs are under development that would specifically target tumors with such ‘loss of function’ in tumor suppressor genes.